Supplementary Data from Tumor-Derived Small Extracellular Vesicles Inhibit the Efficacy of CAR T Cells Against Solid Tumors

Wenqun Zhong,Zhang Xiao,Zhiyuan Qin,Jingbo Yang,Yi Wen,Ziyan Yu,Yumei Li,Neil C. Sheppard,Serge Y. Fuchs,Xiaowei Xu,Meenhard Herlyn,Carl H. June,Ellen Puré,Wei Guo

DOI: https://doi.org/10.1158/0008-5472.23952936.v1

2023-01-01

Abstract:Supplementary Figures and Figure Legends

What problem does this paper attempt to address?

Supplementary Data from Tumor-Derived Small Extracellular Vesicles Inhibit the Efficacy of CAR T Cells against Solid Tumors

Wenqun Zhong,Zebin Xiao,Zhiyuan Qin,Jingbo Yang,Yi Wen,Ziyan Yu,Yumei Li,Neil C. Sheppard,Serge Y. Fuchs,Xiaowei Xu,Meenhard Herlyn,Carl H. June,Ellen Puré,Wei Guo

DOI: https://doi.org/10.1158/0008-5472.23907869

2023-01-01

Abstract:Supplementary Figures and Figure Legends
Supplementary Figures from Targeting Triple-Negative Breast Cancer with Combination Therapy of EGFR CAR T Cells and CDK7 Inhibition

Xin Lin,Zaozao Zheng,Junyi Liu,Yujie Chen,Junqiang Ding,Guosheng Hu,Yahong Hu,Suling Liu,Wenxin Luo,Ningshao Xia,Wen Li

DOI: https://doi.org/10.1158/2326-6066.22543596.v1

2023-01-01

Abstract:All Supplementary Figures (1-9)
Supplemental Data from Cytokine-like Molecule CCDC134 Contributes to CD8+ T-cell Effector Functions in Cancer Immunotherapy

Jing Huang,Lin Xiao,Xiaoting Gong,Wenwei Shao,Yanhui Yin,Qinyuan Liao,Yang Meng,Yingmei Zhang,Dalong Ma,Xiaoyan Qiu

DOI: https://doi.org/10.1158/0008-5472.22402070.v1

2023-01-01

Abstract:Supplemental materials and methods and legends for all supplemental figures.
Supplementary Figure Legends 1-8 from LIGHT Delivery to Tumors by Mesenchymal Stem Cells Mobilizes an Effective Antitumor Immune Response

Weibin Zou,Huilin Zheng,Tong-Chuan He,Jinjia Chang,Yang-Xin Fu,Weimin Fan

DOI: https://doi.org/10.1158/0008-5472.22392851.v1

2023-01-01

Abstract:PDF file - 164K
Supplementary Figure Legends from Nuclear Export of Ubiquitinated Proteins Determines the Sensitivity of Colorectal Cancer to Proteasome Inhibitor

Tingyu Wu,Wei Chen,Yongwang Zhong,Xiaodan Hou,Shengyun Fang,Chen-Ying Liu,Guanghui Wang,Tong Yu,Yu-Yang Huang,Xuesong Ouyang,Henry Q.X. Li,Long Cui,Yili Yang

DOI: https://doi.org/10.1158/1535-7163.22507968.v1

2023-01-01

Abstract:Bortezomib and KPT330 co-treatment inhibit patients-derived xenografts in nude mice.
Supplementary Figure Legends from EpCAM Inhibition Sensitizes Chemoresistant Leukemia to Immune Surveillance

Xin Zheng,Xiaolei Fan,Binqing Fu,Ming–Hua Zheng,Aimei Zhang,Kai Zhong,Jun Yan,Rui Sun,Zhigang Tian,Wei H

DOI: https://doi.org/10.1158/0008-5472.22414839.v1

2023-01-01

Abstract:Supplementary Figure 1-6 legends
Figure S8 from Peripheral Blood–Derived PD-1/CD28–CD19 CAR–Modified PD-1+ T-Cell Therapy in Patients with Solid Tumors

Zhen Zhang,Xuan Zhao,Qitai Zhao,Xinfeng Chen,Congcong Li,Yaqing Liu,Chunyi Shen,Lijie Song,Lijun Miao,Fuyou Guo,Xiaoning Mou,Jie Zhao,Weiyue Gu,Yi Zhang

DOI: https://doi.org/10.1158/2326-6066.27951165

2024-01-01

Abstract:Supplementary Figure S8. Levels of CAR-T cells and B cells in PB after cell infusion.
Supplementary Data from LRP6 Ectodomain Prevents SDF-1/CXCR4-Induced Breast Cancer Metastasis to Lung

Jiankang Zhang,Jingxiao Chen,Wang Da,Hongyuan Yan,Peng Liu,Evan Ma,Limei Li,Lirong Zheng,Daxin Chen,Zuoren Yu,Chao Liang,Jun Peng,Dan‐ni Ren,Weidong Zhu

DOI: https://doi.org/10.1158/1078-0432.22471844.v1

2023-01-01

Abstract:Supplementary Figures, Figure legends and Tables
Figure S5 from Peripheral Blood–Derived PD-1/CD28–CD19 CAR–Modified PD-1+ T-Cell Therapy in Patients with Solid Tumors

Zhen Zhang,Xuan Zhao,Qitai Zhao,Xinfeng Chen,Congcong Li,Yaqing Liu,Chunyi Shen,Lijie Song,Lijun Miao,Fuyou Guo,Xiaoning Mou,Jie Zhao,Weiyue Gu,Yi Zhang

DOI: https://doi.org/10.1158/2326-6066.27951174

2024-01-01

Abstract:Supplementary Figure S5. Characterization of PD-1+ and PD-1- CD4+ T cells in PB and tumor.
Supplementary Data from Senescent Stromal Cells Promote Cancer Resistance Through SIRT1 Loss-Potentiated Overproduction of Small Extracellular Vesicles

Han Liu,Qilai Long,Shenjun Li,Qixia Xu,Boyi Zhang,Xuefeng Dou,Min Qian,Yannasittha Jiramongkol,Jianming Guo,Lei Cao,Y. Eugene Chin,Eric W.‐F. Lam,Jin Jiang,Yu Sun

DOI: https://doi.org/10.1158/0008-5472.22425771

2023-01-01

Abstract:Antibody information summary.
Figure S2 from Peripheral Blood–Derived PD-1/CD28–CD19 CAR–Modified PD-1+ T-Cell Therapy in Patients with Solid Tumors

Zhen Zhang,Xuan Zhao,Qitai Zhao,Xinfeng Chen,Congcong Li,Yaqing Liu,Chunyi Shen,Lijie Song,Lijun Miao,Fuyou Guo,Xiaoning Mou,Jie Zhao,Weiyue Gu,Yi Zhang

DOI: https://doi.org/10.1158/2326-6066.27951183

2024-01-01

Abstract:Supplementary Figure S2. Quality control of scRNA-seq data.
Supplementary Data from the Mechanism of Anti–PD-L1 Antibody Efficacy Against PD-L1–Negative Tumors Identifies NK Cells Expressing PD-L1 As a Cytolytic Effector

Wenjuan Dong,Xiaojin Wu,Shoubao Ma,Yufeng Wang,Ansel P. Nalin,Zheng Zhu,Jianying Zhang,Don M. Benson,Kai He,Michael A. Caligiuri,Jianhua Yu

DOI: https://doi.org/10.1158/2159-8290.22532669.v1

2023-01-01

Abstract:Supplementary figures and figure legends as well as supplementary methods and materials
Supplementary Data from Targeting PIM Kinase with PD1 Inhibition Improves Immunotherapeutic Antitumor T-cell Response

Shilpak Chatterjee,Paramita Chakraborty,Anusara Daenthanasanmak,Supinya Iamsawat,Gabriela Andrejeva,Libia A. Luevano,Melissa Wolf,Uday Baliga,Carsten Krieg,Craig C. Beeson,Meenal Mehrotra,Elizabeth G. Hill,Jeffery C. Rathmell,Xue-Zhong Yu,Andrew S. Kraft,Shikhar Mehrotra

DOI: https://doi.org/10.1158/1078-0432.22469031

2023-01-01

Abstract:Supplementary Figures and Figure Legends
Supplementary Figure from the Antitumor Effects of Vaccine-Activated CD8+ T Cells Associate with Weak TCR Signaling and Induction of Stem-Like Memory T Cells

Sha Wu,Wei Zhu,Yibing Peng,Lan Wang,Yuan Hong,Lei Huang,Dayong Dong,Junping Xie,Todd Merchen,Edward Kruse,Zong Sheng Guo,David Bartlett,Ning Fu,Yukai He

DOI: https://doi.org/10.1158/2326-6066.cir-17-0016

IF: 10.1

2017-01-01

Cancer Immunology Research

Abstract:Supplementary Figure from The Antitumor Effects of Vaccine-Activated CD8+ T Cells Associate with Weak TCR Signaling and Induction of Stem-Like Memory T Cells
Figure S1 from Peripheral Blood–Derived PD-1/CD28–CD19 CAR–Modified PD-1+ T-Cell Therapy in Patients with Solid Tumors

Zhen Zhang,Xuan Zhao,Qitai Zhao,Xinfeng Chen,Congcong Li,Yaqing Liu,Chunyi Shen,Lijie Song,Lijun Miao,Fuyou Guo,Xiaoning Mou,Jie Zhao,Weiyue Gu,Yi Zhang

DOI: https://doi.org/10.1158/2326-6066.27951186

2024-01-01

Abstract:Supplementary Figure S1. Construction of PD-1/CD28 receptor, CD19 CAR and PD-1/CD28-T2A-CD19 CAR.
Supplementary Table 2 from Targeting Triple-Negative Breast Cancer with Combination Therapy of EGFR CAR T Cells and CDK7 Inhibition

Lin Xia,Zaozao Zheng,Jun-yi Liu,Yu-jie Chen,Jiancheng Ding,Guo-sheng Hu,Ya-hong Hu,Suling Liu,Wen-xin Luo,Ning-shao Xia,Wen Liu

DOI: https://doi.org/10.1158/2326-6066.22543587

2023-01-01

Abstract:<p>Supplementary Table 2</p>
Supplementary Figure Legends from Retinoic Acid–Related Orphan Receptor C Regulates Proliferation, Glycolysis, and Chemoresistance Via the PD-L1/ITGB6/STAT3 Signaling Axis in Bladder Cancer

Dalong Cao,Zihao Qi,Yangyang Pang,Haoran Li,Huyang Xie,Junlong Wu,Yongqiang Huang,Yao Zhu,Yijun Shen,Yiping Zhu,Bo Dai,Xin Hu,Dingwei Ye,Ziliang Wang

DOI: https://doi.org/10.1158/0008-5472.22418970

2023-01-01

Abstract:Supplementary Figure Legends
Supplementary Figure S5 from Reconstitution of the Multiple Myeloma Microenvironment Following Lymphodepletion with BCMA CAR-T Therapy

Yazi Yang,Sen Qin,Mengyu Yang,Ting Wang,Ru Feng,Chunli Zhang,Enrun Zheng,Qinghua Li,Pengyu Xiang,Shangyong Ning,Xiaodong Xu,Xin Zuo,Shuai Zhang,Xiaoya Yun,Xuehong Zhou,Yue Wang,Lin He,Yongfeng Shang,Luyang Sun,Hui Liu

DOI: https://doi.org/10.1158/1078-0432.27013660

2024-01-01

Abstract:Supplementary Figure S5. BCMA CAR-T Therapy Enhances the Proportion and Cytotoxic Activity of CD8+ Effector T Cells, Positively Correlating with Therapeutic Responsivity.
Supplementary Figure S6 from Reconstitution of the Multiple Myeloma Microenvironment Following Lymphodepletion with BCMA CAR-T Therapy

Yazi Yang,Sen Qin,Mengyu Yang,Ting Wang,Ru Feng,Chunli Zhang,Enrun Zheng,Qinghua Li,Pengyu Xiang,Shangyong Ning,Xiaodong Xu,Xin Zuo,Shuai Zhang,Xiaoya Yun,Xuehong Zhou,Yue Wang,Lin He,Yongfeng Shang,Luyang Sun,Hui Liu

DOI: https://doi.org/10.1158/1078-0432.27013657.v1

2024-01-01

Abstract:Supplementary Figure S6. BCMA CAR-T Therapy Enhances the Proportion and Cytotoxic Activity of CD8+ Effector T Cells, Positively Correlating with Therapeutic Responsivity.

Supplementary Data from Tumor-Derived Small Extracellular Vesicles Inhibit the Efficacy of CAR T Cells Against Solid Tumors

Supplementary Data from Tumor-Derived Small Extracellular Vesicles Inhibit the Efficacy of CAR T Cells against Solid Tumors

Supplementary Figures from Targeting Triple-Negative Breast Cancer with Combination Therapy of EGFR CAR T Cells and CDK7 Inhibition

Supplemental Data from Cytokine-like Molecule CCDC134 Contributes to CD8+ T-cell Effector Functions in Cancer Immunotherapy

Supplementary Figure Legends 1-8 from LIGHT Delivery to Tumors by Mesenchymal Stem Cells Mobilizes an Effective Antitumor Immune Response

Supplementary Figure Legends from Nuclear Export of Ubiquitinated Proteins Determines the Sensitivity of Colorectal Cancer to Proteasome Inhibitor

Supplementary Figure Legends from EpCAM Inhibition Sensitizes Chemoresistant Leukemia to Immune Surveillance

Figure S8 from Peripheral Blood–Derived PD-1/CD28–CD19 CAR–Modified PD-1+ T-Cell Therapy in Patients with Solid Tumors

Supplementary Data from LRP6 Ectodomain Prevents SDF-1/CXCR4-Induced Breast Cancer Metastasis to Lung

Figure S5 from Peripheral Blood–Derived PD-1/CD28–CD19 CAR–Modified PD-1+ T-Cell Therapy in Patients with Solid Tumors

Supplementary Data from Senescent Stromal Cells Promote Cancer Resistance Through SIRT1 Loss-Potentiated Overproduction of Small Extracellular Vesicles

Figure S2 from Peripheral Blood–Derived PD-1/CD28–CD19 CAR–Modified PD-1+ T-Cell Therapy in Patients with Solid Tumors

Supplementary Data from the Mechanism of Anti–PD-L1 Antibody Efficacy Against PD-L1–Negative Tumors Identifies NK Cells Expressing PD-L1 As a Cytolytic Effector

Supplementary Data from Targeting PIM Kinase with PD1 Inhibition Improves Immunotherapeutic Antitumor T-cell Response

Supplementary Figure from the Antitumor Effects of Vaccine-Activated CD8+ T Cells Associate with Weak TCR Signaling and Induction of Stem-Like Memory T Cells

Figure S1 from Peripheral Blood–Derived PD-1/CD28–CD19 CAR–Modified PD-1+ T-Cell Therapy in Patients with Solid Tumors

Supplementary Table 2 from Targeting Triple-Negative Breast Cancer with Combination Therapy of EGFR CAR T Cells and CDK7 Inhibition

Supplementary Figure Legends from Retinoic Acid–Related Orphan Receptor C Regulates Proliferation, Glycolysis, and Chemoresistance Via the PD-L1/ITGB6/STAT3 Signaling Axis in Bladder Cancer

Supplementary Figure S5 from Reconstitution of the Multiple Myeloma Microenvironment Following Lymphodepletion with BCMA CAR-T Therapy

Supplementary Figure S6 from Reconstitution of the Multiple Myeloma Microenvironment Following Lymphodepletion with BCMA CAR-T Therapy